A world-class management team with over 100 years of combined experience in gene therapy, rare disease drug development and commercialization, and biologics manufacturing.
Mr. Patterson currently serves as Chairman of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector. He is a member of the Board of Directors for Homology Medicines, Inc. and Modis Therapeutics, Inc. Mr. Patterson received his Bachelor’s degree in Biochemistry from Bowdoin College.
Previously Ms. Holles served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc. from 2013 through its acquisition by Horizon Pharma, plc in May 2015. From 2010-2013, Ms. Holles provided executive-level strategy and business development advisory services to a number of privately-held biopharmaceutical companies. Earlier in her career, Ms. Holles served as Vice President, Business Development at KAI Pharmaceuticals, Inc. (acquired by Amgen in 2012) and previously held corporate development and commercial roles at InterMune, Inc. (acquired by Roche in 2014) and Genentech, Inc.
Ms. Holles is a member of the Board of Directors for Rubius Therapeutics, Inc. She holds an M.A. in Molecular, Cellular, and Developmental Biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute Predoctoral Fellow, and an A.B. in Human Biology from Stanford University.
Previously, Mr. Soloway served as the Senior Vice President, Chief Financial Officer of Ascendis Pharma A/S, a Danish biopharmaceutical company. Prior to Ascendis, Mr. Soloway co-founded Transcept Pharmaceuticals, Inc. At Transcept, Mr. Soloway held positions of increasing responsibility, serving initially as Senior Vice President, Operations and Chief Financial Officer and over time as Executive Vice President, Chief Operating Officer. In this role he oversaw project planning, manufacturing, pharmaceutical sciences, legal, human resources, regulatory, and corporate communications. Prior to joining Transcept, Mr. Soloway financed and advised early stage healthcare and life sciences companies as a Principal at Montreux Equity Partners, a venture capital firm.
Mr. Soloway earned a B.S. in Entrepreneurial Studies from the University of Southern California and an M.B.A. from Georgetown University.
Dr. Conner joins Audentes from Sangamo Therapeutics, Inc. where he served as Senior Vice President and Chief Medical Officer and led the clinical development of the company’s pipeline of genomic therapies. Prior to Sangamo, Ed served as Vice President, Global Clinical Development at Ultragenyx Pharmaceutical Inc. where he led the global clinical development efforts for two of the company’s rare disease product candidates. Previously, Ed served as Senior Medical Director at BioMarin Pharmaceutical Inc. where he led clinical development and regulatory interactions for its global Phase 3 program in Pompe disease, and earlier in his career Dr. Conner served as Medical Director at Genentech, Inc. where he was the clinical science team leader of two product candidates, including XOLAIR®.
Dr. Conner completed his Internal Medicine residency training at the University of Michigan and was a fellow in Clinical Immunology and Allergic Diseases at Johns Hopkins School of Medicine. He earned a B.S. in Biology, cum laude, from Duke University and his M.D. from the University of California, San Francisco.
Eric B. Mosbrooker has served as Senior Vice President and Chief Commercial Officer (CCO) at Audentes Therapeutics since January 2019. He brings more than 15 years of healthcare leadership experience focused on launching and commercializing treatments for rare and orphan diseases. As CCO, Mr. Mosbrooker is responsible for executing the global commercial strategy for the company’s growing portfolio of gene therapy product candidates, and for building the commercial organization, including patient services, sales, marketing, and market access teams.
Mr. Mosbrooker joined Audentes from Origin Biosciences, a subsidiary of BridgeBio Pharma and a biotechnology company focused on developing a treatment for molybdenum cofactor deficiency (MoCD) type A, a rare pediatric metabolic disorder, where he served as Chief Operating Officer. Prior to Origin Biosciences, Mr. Mosbrooker led the orphan business at Horizon Pharma after its acquisition of Raptor Pharmaceuticals. At Raptor, he was the Senior Vice President of Americas & Asia Pacific, where he led the U.S. launch of Procysbi®, a drug for the treatment of nephropathic cystinosis. Previously, Mr. Mosbrooker served as the lead for commercial operations and market access for Strensiq® at Alexion and Enobia Pharma, Inc. He also served in various commercial operational capacities at Onyx Pharmaceuticals, Jazz Pharmaceuticals Inc., Chiron Corporation (now Novartis), and Millennium Pharmaceuticals. Additionally, he has extensive experience in management, healthcare, and technology consulting at IBM, Teltech Resource Network Corporation, and Kohler Company. Mr. Mosbrooker earned his B.S. in Industrial Engineering from the University of Wisconsin, Madison.
Mark Meltz, J.D., is Senior Vice President and General Counsel at Audentes Therapeutics and is responsible for leading the legal, compliance, and corporate governance functions for the company. He brings nearly 20 years of leadership experience working in various roles at global pharmaceutical and biotechnology companies as well as a top international law firm.
Mr. Meltz joined Audentes from PaxVax, a specialty vaccines company, where he managed business development, legal, compliance, and government affairs/public policy functions, and led the company’s October 2018 sale to Emergent BioSolutions. Prior to joining PaxVax, Mr. Meltz worked at Biogen Idec (now Biogen), where he served as the lead lawyer for the global medical affairs group and the lead U.S. commercial lawyer for the multiple sclerosis products Tysabri® and Tecfidera® (including for its U.S. launch) . Earlier in his career, Mr. Meltz served as Head of Legal for Novartis Vaccines for the Americas and North America regions (including for the U.S. launch of the meningitis vaccine Menveo®). Before joining the industry, Mr. Meltz practiced law at the international law firm Bingham McCutchen LLP (now part of Morgan Lewis & Bockius LLP), where he focused on mergers and acquisitions, venture capital financing, securities regulation, and general corporate matters. Mr. Meltz earned his J.D. from Boston College Law School, Magna Cum Laude, and his B.A. with Departmental Honors in Psychology from Yale University.
Fulvio Mavilio, Ph.D. is Senior Vice President of Translational Science at Audentes Therapeutics. He joined the company as Vice President Scientific Affairs, Europe in July 2017. A highly regarded expert and pioneer in the gene therapy field, Dr. Mavilio is responsible for advancing the company’s pipeline from discovery to clinical development overseeing molecular biology, in vivo pharmacology, bioinformatics, and bioanalytics at Audentes.
Prior to joining Audentes, Dr. Mavilio served as Chief Scientific Officer of Genethon in Evry, France from 2012 to 2017 where he led the development of a robust pipeline of gene therapy programs for blood, liver, and neuromuscular diseases. Previously, he was co-Director of the Center for Regenerative Medicine of the University of Modena, Italy from 2006 to 2011, Director of Discovery of Molmed SpA from 2002 to 2005, founder and Chief Scientific Officer of Genera SpA from 1999 to 2002, and co-Director of the San Raffaele-Telethon Institute of Gene Therapy in Milan, Italy from 1995 to 2002. Under these tenures, he designed and developed gene therapies for inherited and acquired diseases, including the pioneer treatment for adenosine deaminase deficiency that became the first ex vivo gene therapy to receive marking authorization in Europe.
Dr. Mavilio is a member of the European Molecular Biology Association (EMBO), past member of the Board of the American Society of Gene and Cell Therapy (ASGCT), and a member of the Editorial Board of many international journals in the fields of genetics, molecular biology, and gene therapy. He earned an undergraduate degree in Biology at the University of Rome in 1976 and a Ph.D. in Medical Genetics at the University of Rome School of Medicine in 1979. He also trained as a visiting scientist at the Wistar Institute in Philadelphia, PA from 1985 to 1989. Dr. Mavilio has published more than 190 articles in major international journals. He also serves as Professor of Molecular Biology at the University of Modena and Reggio Emilia in Modena, Italy.
Mary Newman is Senior Vice President of Regulatory Affairs at Audentes Therapeutics. She joined the company with more than 20 years of experience in regulatory affairs and research and development within the biotechnology industry, focusing on rare diseases. Ms. Newman oversees global regulatory strategic development, all primary regulatory agency interactions, and regulatory compliance for Audentes’ development candidates.
Prior to joining Audentes, Ms. Newman served as the Senior Vice President, Regulatory Affairs and Quality Assurance at SARcode Bioscience Inc., which was acquired by Shire Ltd. She previously held various management positions, with increasing responsibility in Regulatory Affairs at BioMarin Pharmaceutical, Inc., Berlex Inc. (now Bayer HealthCare Pharmaceuticals Inc.), and Sequus Pharmaceuticals, Inc. (now Johnson & Johnson). While at BioMarin, Ms. Newman oversaw the development and approval of Kuvan® for the treatment of phenylketonuria (PKU), Naglazyme® for mucopolysaccharidosis (MPS) VI, and supported the final approval of Aldurazyme® for MPS I. She has also held various research and development leadership roles in oncology, neurology, and antifungal therapeutic areas.
Ms. Newman holds a B.S. in Physiology from Oregon State University.
Salvador Rico, M.D., Ph.D. is Senior Vice President of Clinical Development at Audentes Therapeutics. He is a clinical pharmacologist with 15 years of clinical research experience in the pharmaceutical industry, contract research organizations and academia. Dr. Rico has participated in the design, conduct, and analysis of Phase I-IV clinical trials in multiple therapeutic areas, including rare diseases, hematology/oncology, transfusion medicine, psychiatry, sleep medicine, cardiovascular medicine, infectious diseases, pain, allergy, and dermatology.
Prior to joining Audentes he led the clinical development teams at Cerus Corporation and Transcept Pharmaceuticals and was an investigator at the Centre for Drug Research, Hospital de la Santa Creu i Sant Pau in Barcelona, Spain. His clinical research and development experience includes drugs, biological products, and medical devices, such as the INTERCEPT Blood System®, Intermezzo®, Hibor®, Champix®, Prolia® and Kerydin®, among others.
Dr. Rico was awarded a Doctor of Medicine and Surgery degree from the National Autonomous University of Mexico and holds a Master’s in Science and a Ph.D. in Pharmacology from the Universitat Autonoma de Barcelona (Summa Cum Laude). Additionally, he has received postdoctoral training in clinical pharmacology, transfusion medicine, and pharmaceutical medicine.
Donald Wuchterl has served as Senior Vice President of Technical Operations at Audentes Therapeutics since January 2016. He is responsible for the company’s Quality, Manufacturing, Supply Chain, Facilities & Engineering, and Process & Analytical Development teams.
Mr. Wucheterl has more than 25 years of experience in manufacturing clinical and commercial GMP products including biologics, small molecules, cellular immunotherapies, and AAV gene therapies. Mr. Wuchterl has extensive experience in the design, buildout, validation, licensure, and operation of these facilities.
Mr. Wuchterl joined Audentes from Cytovance Biologics where he was Senior Vice President and Chief Operating Officer. Prior to Cytovance, Mr. Wuchterl held positions of increasing responsibility in manufacturing and operations-related roles at Dendreon, Shire HGT, Amgen, Biogen Idec, and Roche.
Mr. Wuchterl holds a B.S. in Business Administration from Colorado Technical University and a M.B.A. from Fitchburg State University.
Dr. Lange holds a Ph.D. degree in Biochemistry from Harvard University and an M.D. degree from Harvard Medical School. Dr. Lange has a Bachelor’s degree from the University of Rochester.
Dr. Goldberg is a board certified medical oncologist and hematologist, having received his A.B. (magna cum laude) from Harvard College and his M.D. (cum laude) from Harvard Medical School.
Prior to Citigroup, Ms. Jarrett was a Managing Director in Credit Suisse’s Health Care Group focused on the biotechnology sector. She earned a bachelor’s degree in economics, Cum Laude, from Dartmouth College and holds an M.B.A. from Stanford Graduate School of Business.